NXRT vs NVCR

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -3. 2% for NexPoint Residential Trust, Inc. (NXRT). Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, NexPoint Residential Trust, Inc.

(NXRT) delivered a total return of -20. 9%, compared to -92. 1% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NXRT returned +216. 0% versus NVCR's +40. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), NexPoint Residential Trust, Inc.

(NXRT) is the lower-risk stock at 0. 62β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 254% more volatile than NXRT relative to the S&P 500. On balance sheet safety, NovoCure Limited (NVCR) carries a lower debt/equity ratio of 85% versus 5% for NexPoint Residential Trust, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -3. 2% for NexPoint Residential Trust, Inc. (NXRT). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -30. 8% for NexPoint Residential Trust, Inc.. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

NexPoint Residential Trust, Inc.

(NXRT) is the more profitable company, earning -12. 7% net margin versus -20. 8% for NovoCure Limited — meaning it keeps -12. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NXRT leads at 11. 1% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NXRT leads at 84. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, NXRT (7.

2% yield) pays a dividend. NVCR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, NexPoint Residential Trust, Inc.

(NXRT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 62), 7. 2% yield, +216. 0% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NXRT: +216. 0%, NVCR: +40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NXRT (Real Estate) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NXRT is a small-cap income-oriented stock; NVCR is a small-cap quality compounder stock. NXRT pays a dividend while NVCR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.